1. Introduction {#sec1-jcm-09-01633}
===============

Atrial fibrillation (AF) is the most common type of arrhythmia in the USA and European countries, with a current estimated prevalence between 1% and 4% \[[@B1-jcm-09-01633]\]. Its prevalence is of critical concern owing to its cardiovascular complications such as ischemic stroke, heart failure, and increasing mortality \[[@B2-jcm-09-01633]\]. Obesity, another prevalent condition worldwide, was estimated to cause 3.4 million deaths in 2010. If current trends continue, forecasts estimate that 1 billion adults will be obese by the year 2030 \[[@B3-jcm-09-01633]\]. Moreover, obesity has been linked with AF, due to its association with obstructive sleep apnea, diabetes mellitus, hypertension, left ventricular dysfunction, heart failure with preserved left ventricular function, and left atrial enlargement \[[@B4-jcm-09-01633],[@B5-jcm-09-01633],[@B6-jcm-09-01633]\]. It has also been associated with hypofibrinolysis, inflammation, and a prothrombotic state, further bolstering the link with the thromboembolic effects of AF \[[@B4-jcm-09-01633],[@B5-jcm-09-01633]\].

In the Atherosclerosis Risk in Communities (ARIC) study, obesity and overweight accounted for 17.9% of all AF cases \[[@B6-jcm-09-01633]\]. Though AF risk appears to follow a linear relationship with an increase in BMI, the pathophysiological basis of the obesity--AF relationship is complex and multifactorial \[[@B7-jcm-09-01633]\]. Exploring the risk of stroke in a subgroup of an AF population with obesity is paramount due to prevalence and the potential for high morbidity and mortality.

In the years since their approval, non-vitamin K oral anticoagulants (NOACs) have been increasingly preferred over warfarin due to the convenience of fewer routine monitoring visits, no requirements for dose adjustment, and limited dietary interactions. With the current fixed-dose NOAC prescriptions, the clinical impact of anticoagulation on non-valvular atrial fibrillation (NVAF) patients with obesity is expected to be similar, provided patients have optimum peak and trough levels of NOACs \[[@B8-jcm-09-01633]\]. The International Society of Thrombosis and Hemostasis recommends the standard dosing of NOACs in patients with obesity and with a BMI ≤ 40 or weight ≤ 120 kg but suggests that NOACs should not be used among patients with a BMI \> 40 or weight \> 120 kg because there is limited clinical data for these patients \[[@B9-jcm-09-01633],[@B10-jcm-09-01633]\]. The use of NOACs in patients with morbid obesity has not been as well-documented or established. Therefore, comparing the risk of stroke and major bleeding (MB) in a real-world population of NVAF patients with obesity and morbid obesity among oral anticoagulant (OAC) users is crucial.

The NOAC clinical trials RE-LY and ROCKET-AF suggested that there was no significant interaction between weight categories (≥100 kg vs. \<100 kg) regarding the impact of dabigatran and rivaroxaban versus warfarin on the risk of stroke/systemic embolism (SE) \[[@B11-jcm-09-01633],[@B12-jcm-09-01633]\]. A similar risk of major and clinically relevant non-MB was also seen among the subgroup with obesity for rivaroxaban vs. warfarin in the ROCKET-AF trial \[[@B12-jcm-09-01633]\]. A post-hoc analysis using the patients in the ARISTOTLE trial showed evidence of significant interaction between BMI and MB, comparing apixaban vs. warfarin, with a larger reduction in MB with normal vs. higher BMI \[[@B13-jcm-09-01633]\].

Additionally, several observational studies evaluating patients with morbid obesity (BMI ≥ 35 or BMI ≥ 40, depending on the source) showed that NOACs had a similar risk of stroke/SE and MB compared to warfarin \[[@B14-jcm-09-01633],[@B15-jcm-09-01633],[@B16-jcm-09-01633],[@B17-jcm-09-01633]\]. While they add valuable knowledge regarding the clinical course of patients with obesity and morbid obesity, existing real-world studies have limitations (e.g., small sample size and no individual NOAC comparisons) that suggest the need for the further evaluation of NOAC treatment in these populations. Larger real-world studies may be warranted to further examine the use of NOACs in this high-risk population with obesity. Using several data sources, this subgroup analysis of ARISTOPHANES (Anticoagulants for Reduction In Stroke: Observational Pooled analysis on Health outcomes And Experience of Patients; NCT03087487) aimed to respectively compare the risk of stroke/SE and MB among the NVAF population with obesity newly prescribed apixaban, dabigatran, rivaroxaban, or warfarin.

2. Experimental Section {#sec2-jcm-09-01633}
=======================

2.1. Data Sources {#sec2dot1-jcm-09-01633}
-----------------

This study was a retrospective observational database analysis of a patient population of \>180 million beneficiaries per year (\~56% of the United States population), using fee-for-service (FFS) Medicare data from the US Centers for Medicare & Medicaid Services (CMS) and four US commercial claims databases: the IBM MarketScan^®^ Commercial Claims and Encounter Database, the IQVIA PharMetrics Plus™ Database, the Optum Clinformatics™ Data Mart, and the Humana Research Database. The databases include patients with Medicare FFS, Medicare Advantage, and commercial insurance. Database records include comprehensive demographic and clinical information and International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes, Healthcare Common Procedure Coding System codes, and National Drug Codes. Previously published articles include detailed descriptions of the datasets, the rationale for the pooling process, and the approaches to minimizing potential patient record duplicates across data sources \[[@B18-jcm-09-01633],[@B19-jcm-09-01633]\].

2.2. Patient Selection {#sec2dot2-jcm-09-01633}
----------------------

NVAF patients diagnosed with obesity were selected if they had ≥1 pharmacy claim for apixaban, dabigatran, rivaroxaban, or warfarin between 01 January 2013 and 30 September 2015 (identification period). Edoxaban was excluded from the final sample due to small sample size. Obesity is typically defined as a BMI ≥ 30 kg/m^2^ \[[@B20-jcm-09-01633]\] and was defined here by the presence of a diagnosis code containing obesity or an obese BMI designation ([Table A1](#jcm-09-01633-t0A1){ref-type="table"}). The first NOAC prescription date was designated as the index date if patients had a NOAC claim. The first warfarin prescription date was designated as the index date for patients without any NOAC claim. Patients were required to have an AF diagnosis before or on the index date and have continuous medical and pharmacy health plan enrollment for ≥12 months pre-index date (baseline period).

To evaluate new initiators, patients treated with an OAC within 12 months pre-index date were excluded. Patients were also excluded if they had claims indicating any of the following: valvular heart disease, venous thromboembolism, transient AF (pericarditis, hyperthyroidism, or thyrotoxicity), heart valve replacement/transplant, or cardiac surgery during the baseline period; pregnancy during the study period; or hip or knee replacement surgery within 6 weeks pre-index date. In addition, patients were excluded if they had \>1 OAC on the index date or had no follow-up. Lastly, patients with claims containing ICD-10 codes were excluded to ensure accurate classification, as the ICD-10-CM coding system was not fully adopted in the United States until 1 October 2015, after the study period ended.

2.3. Outcome Measures {#sec2dot3-jcm-09-01633}
---------------------

The outcome measures were time to first stroke/SE, including ischemic stroke, hemorrhagic stroke, and SE; and time to first MB, including gastrointestinal (GI) bleeding, intracranial hemorrhage, and bleeding at other key sites (e.g., the genitourinary tract, respiratory tract, or ocular area; [Table A1](#jcm-09-01633-t0A1){ref-type="table"}) \[[@B21-jcm-09-01633],[@B22-jcm-09-01633]\]. Outcomes were based on hospitalizations with stroke/SE or MB as the principal or first-listed diagnosis. The follow-up period ranged from one day post-index date to 30 days after discontinuation, the switch date, death (only inpatient death for the commercial databases and all-cause death for the Medicare database), the end of continuous medical or pharmacy plan enrollment, or the end of the study (30 September 2015), whichever came first.

2.4. Statistical Methods {#sec2dot4-jcm-09-01633}
------------------------

Propensity score matching (PSM) was conducted between the NOAC and warfarin cohorts (apixaban vs. warfarin, dabigatran vs. warfarin, and rivaroxaban vs. warfarin) and between the NOAC cohorts (apixaban vs. dabigatran, apixaban vs. rivaroxaban, and dabigatran vs. rivaroxaban). Patients were matched 1:1 in each dataset based on the propensity scores generated by logistic regression using demographics, Charlson comorbidity index scores \[[@B23-jcm-09-01633]\], comorbidities, and baseline co-medications. Patients were matched by nearest neighbor matching without replacement (with a caliper of 0.01). Covariate balance was checked through standardized differences, with a threshold of 10% \[[@B24-jcm-09-01633]\]. After ensuring the cohorts were balanced in each database, study patients from the five datasets were pooled for analysis.

The risks of stroke/SE and MB were evaluated using Cox proportional hazard models, with robust sandwich estimates \[[@B25-jcm-09-01633]\]. *p*-values \< 0.05 were considered statistically significant. OAC treatment was included as the independent variable; as the cohorts were balanced, no other covariates were included in the model.

2.5. Subgroup Analyses {#sec2dot5-jcm-09-01633}
----------------------

Two subgroup analyses were conducted. First, PSM and Cox proportional hazard models were completed for patients prescribed standard dose NOACs (apixaban 5 mg twice a day (BID), dabigatran 150 mg BID, rivaroxaban 20 mg once a day (QD)). A second subgroup analysis was conducted among patients with morbid obesity. Patients with morbid obesity were defined using diagnosis codes indicating morbid obesity or a BMI ≥ 40 and were re-matched ([Table A1](#jcm-09-01633-t0A1){ref-type="table"}) \[[@B15-jcm-09-01633]\]. For both subgroup analyses, the same methodology as that for the main analysis was used.

Institutional Review Board approval was not required because the study did not involve the collection, use, or transmittal of individual identifiable data. Both the datasets and the security of the offices where analysis was completed (and where the datasets are kept) met the requirements of the Health Insurance Portability and Accountability Act of 1996.

3. Results {#sec3-jcm-09-01633}
==========

After applying the selection criteria, a total of 88,461 (18.9%) NVAF patients with obesity were identified, including 21,242 apixaban (24.0%), 7171 dabigatran (8.1%), 29,146 rivaroxaban (32.9%), and 30,902 warfarin (34.9%) patients ([Figure 1](#jcm-09-01633-f001){ref-type="fig"}). Before PSM, the warfarin patients were the oldest and had the highest CHA~2~DS~2~-VASc and HAS-BLED scores, followed by apixaban, rivaroxaban, and dabigatran patients ([Table A2](#jcm-09-01633-t0A2){ref-type="table"}).

The unadjusted incidence rates of stroke/SE were 2.0, 1.3, 1.5, and 1.3 for warfarin, apixaban, dabigatran, and rivaroxaban per 100 person-years, respectively. The unadjusted rates for MB were 7.6, 3.9, 4.0, and 6.0 per 100 person-years for warfarin, apixaban, dabigatran, and rivaroxaban, respectively ([Table A3](#jcm-09-01633-t0A3){ref-type="table"}).

The PSM procedure resulted in 18,181 pairs for the apixaban-warfarin, 6646 pairs for the dabigatran-warfarin, and 22,053 pairs for the rivaroxaban-warfarin cohorts with obesity. Matching for NOAC comparisons included 6884 patient pairs for the apixaban-dabigatran, 20,431 pairs for the apixaban-rivaroxaban, and 7103 pairs for the dabigatran-rivaroxaban cohorts ([Figure 1](#jcm-09-01633-f001){ref-type="fig"}). The mean follow-up time for the six matched cohorts ranged from 6 to 8 months. Within NOAC vs. warfarin comparisons, patients prescribed standard doses of NOACs included 84.8% of apixaban (5 mg), 86.5% of dabigatran (150 mg) and 75.3% of rivaroxaban (20 mg) patients. Select baseline characteristics of the matched populations are shown in [Table 1](#jcm-09-01633-t001){ref-type="table"}a,b. After matching, all demographic and clinical characteristics were well balanced between pairs (a complete list of baseline variables appears in [Table A4](#jcm-09-01633-t0A4){ref-type="table"} and [Table A5](#jcm-09-01633-t0A5){ref-type="table"}).

3.1. NOAC vs. Warfarin Comparison {#sec3dot1-jcm-09-01633}
---------------------------------

Patients prescribed apixaban and rivaroxaban had a lower risk of stroke/SE compared to warfarin patients (apixaban: hazard ratio (HR): 0.63, 95% confidence interval (CI): 0.49--0.82; rivaroxaban: HR: 0.84, 95% CI: 0.72--0.98), while dabigatran patients had a similar risk of stroke/SE compared to warfarin patients (HR: 1.23, 95% CI: 0.90--1.67). Compared with warfarin, apixaban and dabigatran (HR: 0.54, 95% CI: 0.49--0.61; HR: 0.75, 95% CI: 0.63--0.91, respectively) were associated with a lower risk of MB ([Figure 2](#jcm-09-01633-f002){ref-type="fig"}a). Rivaroxaban had a similar risk of MB (HR: 1.02, 95% CI: 0.90--1.17) compared to warfarin.

3.2. NOAC vs. NOAC Comparisons {#sec3dot2-jcm-09-01633}
------------------------------

Compared to rivaroxaban, apixaban was associated with a lower risk of stroke/SE (HR: 0.78, 95% CI: 0.64--0.94) and MB (HR: 0.52, 95% CI: 0.47--0.59). Compared to dabigatran, apixaban had a non-significant difference for the risk of stroke/SE (HR: 0.71, 95% CI: 0.49--1.04) and a lower risk of MB (HR: 0.78, 95% CI: 0.61--0.99). Dabigatran was associated with a lower risk of MB (HR: 0.67, 95% CI: 0.56--0.81) than rivaroxaban while having a similar risk of stroke/SE (HR: 1.04, 95% CI: 0.72--1.51) ([Figure 2](#jcm-09-01633-f002){ref-type="fig"}b). The Kaplan--Meier curves for the cumulative incidence rates of stroke/SE and MB in the matched populations have been included in [Figure A1](#jcm-09-01633-f0A1){ref-type="fig"}(a)--(l)

3.3. Subgroup Analyses {#sec3dot3-jcm-09-01633}
----------------------

The results of the standard dose subgroup analysis were generally consistent with the main analysis. However, there was no significant difference between apixaban and dabigatran for major bleeding (HR: 0.77, 95% CI: 0.59--1.00) and between apixaban and rivaroxaban for stroke/SE (HR: 0.93, 95% CI: 0.74--1.17). ([Table 2](#jcm-09-01633-t002){ref-type="table"}).

Among all the patients with obesity in the pooled sample, 39.5% were identified as morbidly obese. PSM resulted in 6310 apixaban-warfarin, 2342 dabigatran-warfarin, 8055 rivaroxaban-warfarin, 2373 apixaban-dabigatran, 7180 apixaban-rivaroxaban, and 2617 dabigatran-rivaroxaban pairs of patients. There was no significant difference in the risk of stroke/SE between each NOAC versus warfarin or between NOACs. Apixaban had a lower risk of MB compared to warfarin, dabigatran, and rivaroxaban. Conversely, dabigatran and rivaroxaban were both associated with a similar risk of MB compared to warfarin in the population with morbid obesity ([Table 3](#jcm-09-01633-t003){ref-type="table"}).

4. Discussion {#sec4-jcm-09-01633}
=============

To date, this ARISTOPHANES obesity subgroup analysis is the largest retrospective observational study evaluating the risk of stroke/SE and MB among NVAF patients with obesity who initiated OAC treatment. Due to the increasing prevalence of obesity in the United States, the complexity of case management, and the limited data, we chose to examine the effectiveness and safety of NOACs within an NVAF sub-population with obesity \[[@B3-jcm-09-01633],[@B4-jcm-09-01633]\]. With CMS Medicare and four large US national claims datasets, this study found that NOACs had a varying risk of stroke/SE and MB compared to warfarin and among each other in this population with obesity.

These results are largely consistent with subgroup analysis results from previous randomized controlled trials (RCT)s. Post-hoc obesity analyses from the ARISTOTLE trial demonstrated that BMI (18.5 to 25, 25 to 30, and ≥30) did not have significant interaction with treatment and stroke/SE, death, or MACE (composite of stroke/SE, myocardial infarction, and death) \[[@B13-jcm-09-01633]\]. However, the BMI categories had a significant interaction with MB (P~interaction~ = 0.006); for patients with a BMI ≥ 30, apixaban had a similar risk of MB to warfarin; for patients with normal and overweight BMIs, the risk of MB for apixaban was lower compared to that for warfarin. This trend was also seen in the other BMI categories with varying levels of magnitude. The reason for this is likely multifactorial---it is possible that differences in age and comorbidity levels may confound the risk of bleeding. Sub-analysis from the RE-LY trial examined the effect of dabigatran on the risk of stroke/SE by weight categories (\<50 kg, 50--99 kg and ≥100 kg). The interaction of the weight of patients on dabigatran (110 mg and 150 mg) had no significant effect on the risk of stroke/SE (*p* = 0.48 and *p* = 0.42, respectively) \[[@B11-jcm-09-01633]\]. Additionally, sub-analysis from the ROCKET-AF trial showed no significant interaction between the BMI categories and stroke/SE (*p* = 0.537) and MB outcomes (*p* = 0.310), comparing rivaroxaban and warfarin \[[@B12-jcm-09-01633]\]. Therefore, based on weight or BMI, the referenced trials have demonstrated a similar efficacy and risk of safety outcomes between NOACs and warfarin in a population with obesity. Furthermore, in a meta-analysis of RCTs and observational studies among patients with obesity, NOACs showed a similar risk of stroke/SE (HR: 0.84, 95% CI: 0.70--1.03) and MB (HR: 1.03, 95% CI: 0.90--1.18) compared to warfarin \[[@B26-jcm-09-01633]\].

Apart from RCTs, few real-world studies have compared the effectiveness and safety of OACs in an NVAF population with obesity. Additionally, very few studies have compared NOACs individually rather than as a class. In the Dresden NOAC Registry, based in Germany, there was no indication that increased BMI was associated with a lack of NOAC effectiveness or safety \[[@B27-jcm-09-01633]\]. Just as for obesity, very few studies have evaluated the effectiveness of NOACs in a population with morbid obesity. A retrospective cohort study of 64 patients with morbid obesity (BMI \> 40) found that NOACs had a similar risk of ischemic stroke/transient ischemic attack and MB compared to warfarin \[[@B16-jcm-09-01633]\]. In a recent real-world analysis, the electronic medical records from patients with morbid obesity (BMI \> 40) at Montefiore Medical Center (NY, USA) suggested that apixaban had a similar risk of stroke and bleeding compared to warfarin \[[@B14-jcm-09-01633]\]. Another study from the Montefiore Medical Center found that there was no significant difference in the incidence of stroke or major bleeding between apixaban, rivaroxaban, and warfarin patients \[[@B17-jcm-09-01633]\]. A recent real-world analysis using US Truven MarketScan claims among NVAF patients with morbid obesity found that rivaroxaban showed a similar risk of stroke and MB compared to warfarin \[[@B15-jcm-09-01633]\]. Our analysis on patients with morbid obesity found a similar risk of stroke/SE between NOACs and warfarin and suggested a lower risk of MB with apixaban vs. warfarin, apixaban vs. dabigatran, and apixaban vs. rivaroxaban.

Prior studies have not evaluated the effect of dose among patients with obesity. In our dose subgroup analysis, we found that standard dose apixaban and rivaroxaban were associated with a lower risk of stroke/SE compared to warfarin, and standard-dose apixaban and dabigatran were associated with a lower risk of MB compared to warfarin. In addition to this subgroup analysis, some real-world studies have evaluated the effectiveness of fixed-dose NOACs in patients with obesity \[[@B28-jcm-09-01633]\]. While patients with obesity often require the dose adjustment of drugs due to altered pharmacokinetics, the current recommendations for NOAC therapy imply fixed-dose treatment. Furthermore, it has been found that while the plasma levels of NOACs varied by body weight, the variance was not significant \[[@B28-jcm-09-01633]\]. Further studies are needed to evaluate the use of standard-dose NOACs among patients with obesity.

Compared to previous studies that evaluated the safety and effectiveness of NOACs among NVAF patients with obesity, the ARISTOPHANES pooled study provided a larger sample size with higher statistical power to compare outcomes for each OAC in the NVAF subgroup with obesity. The study findings showed that in this high-risk subgroup of NVAF patients, apixaban and rivaroxaban patients had a lower risk of stroke/SE compared to warfarin patients, and rivaroxaban had a similar risk of MB compared to warfarin. Compared with warfarin, apixaban and dabigatran were associated with a lower risk of MB, while dabigatran patients had a similar risk of stroke/SE. In addition, the study found that compared to dabigatran, apixaban had a non-significant difference for the risk of stroke/SE and had a lower risk of MB. Apixaban patients were also found to have a lower risk of stroke/SE and MB compared to rivaroxaban patients. Dabigatran was associated with a lower risk of MB and a similar risk of stroke/SE when compared to rivaroxaban. These results provide information complementary to the obesity post-hoc and sub-analyses from existing trials. While hypothesis-generating, this real-world evidence supports the fixed dose regimen of NOACs, which appears to maintain safety and effectiveness compared to traditional vitamin K antagonist therapy.

5. Limitations {#sec5-jcm-09-01633}
==============

This retrospective observational study has several limitations. First, only statistical associations could be concluded, not causal relationships. Although cohorts were matched through PSM, there were potential residual confounders. This limitation is especially important for interpreting the NOAC vs. NOAC comparison results, which are intended for hypothesis generation, given the lack of head-to-head trials. In addition, since the two drug cohorts were matched independently, conclusions can only be drawn between the matched cohorts, not across the comparisons. Second, due to the nature of the claims studies, outcome measures could only be based on ICD-9-CM codes without further adjustment with precise clinical criteria. More importantly, obesity indicators were ascertained based on ICD-9-CM coding (for ≥30 BMI or an indication of obesity). Body measurements such as weight or lean body mass were not available in the claims data. A separate analysis was conducted to validate the diagnosis codes used to identify obesity and morbid obesity in this study by using one of the five databases linked with electronic medical records \[[@B29-jcm-09-01633]\]. The results from that study showed the obesity diagnosis codes had high positive predictive value (PPV) (89.8%), high specificity (95.2%), and modest sensitivity (48.7%) among newly treated NVAF patients. The morbid obesity diagnosis codes also had high specificity (96.5%) but modest PPV (67.9%) and sensitivity (62.8%) \[[@B29-jcm-09-01633]\]. The modest sensitivity suggests that we may fail to identify some of the patients with obesity and morbid obesity. The moderate PPV for the morbid obesity diagnosis codes indicates that there may be some misclassified patients in this group.

An additional study limitation is that laboratory values---such as international normalized ratio (INR) measurements---are not available in the dataset, so the time in the therapeutic range for the patients prescribed warfarin was indeterminable. Nonetheless, the inclusion of patients with potentially poorer quality control of warfarin therapy in everyday clinical practice may enable the study findings to better reflect real-world situations. Additionally, unobserved heterogeneity may exist across the five data sources. Finally, the results may not reflect the overall NVAF population in the United States because the study did not include uninsured patients and patients solely covered by other public health insurance plans.

6. Conclusions {#sec6-jcm-09-01633}
==============

This study, the largest observational study of NVAF patients with obesity, shows that NOACs were associated with a varying risk of stroke/SE and MB compared to warfarin and among each other. Apixaban was associated with a lower risk of stroke/SE and MB compared to warfarin. Additionally, compared with warfarin, dabigatran was associated with a lower risk of MB and a similar risk of stroke/SE; rivaroxaban was associated with a lower risk of stroke/SE and a similar risk of MB. Additional real-world studies are warranted in the population with obesity to understand the impact of NOACs on this high-risk group. These findings may help clinicians better understand the differentiated profile of OACs in an NVAF patient population with obesity.
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jcm-09-01633-t0A1_Table A1

###### 

ICD-9-CM diagnosis and procedure codes for selection criteria and outcomes.

  Diagnosis                                                                                                          ICD-9-CM Diagnosis and Procedure Codes
  ------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Atrial Fibrillation                                                                                                427.31
  Valvular Heart Disease                                                                                             394.0, 394.1, 394.2, 394.9, 396.0, 396.1, 396.8, 396.9, 424.0, 745.xx
  Heart Valve Replacement                                                                                            V42.2, V43.3, 35.05--35.09, 35.20--35.28, 35.97
  VTE                                                                                                                451--453, 671.3, 671.4, 671.9, 415.1, 673.2, 673.8
  Transient AF (Heart Valve Replacement/Transplant, Pericarditis, Thyrotoxicity)                                     Pericarditis: 006.8, 017.9, 036.41, 074.21, 093.81, 098.83, 115.93, 390, 391, 392.0, 393, 411.0, 420.90, 420.91, 420.99, 423.0, 423.1, 423.2, 423.8, 423.9
  Thyrotoxicity: 242.0, 242.1, 242.2, 242.3, 242.4, 242.8, 242.9                                                     
  Pregnancy                                                                                                          ICD-9-CM: 630--679, V22, V23, V24, V27, V28, V61.6, V61.7, 792.3, 796.5, 72--75.99
  HCPCS: 59000--59350, 76801--76828, 83661--83664                                                                    
  Obesity                                                                                                            278.00 (obesity, unspecified), 278.01 (morbid obesity), 278.03 (obesity hypoventilation syndrome), V85.3 (BMI of 30--39), V85.4 (BMI 40 and over)
  Morbid Obesity                                                                                                     278.01 (morbid obesity), V85.4 (BMI 40 and over)
  **Outcomes**                                                                                                       
  Hemorrhagic Stroke                                                                                                 430.xx--432.xx
  Cases were excluded if traumatic brain injury (ICD-9-CM: 800--804, 850--854) was present during hospitalization.   
  Ischemic Stroke                                                                                                    433.x1, 434.x1, 436
  Systemic Embolism                                                                                                  444.x, 445.x
  Major Gastrointestinal Bleeding                                                                                    456.0, 456.20, 530.82, 531.0x, 531.2x, 531.4x, 531.6x, 532.0x, 532.2x, 532.4x, 532.6x, 533.0x, 533.2x, 533.4x, 533.6x, 534.0x, 534.2x, 534.4x, 534.6x, 535.01, 535.11, 535.21, 535.31, 535.41, 535.51, 535.61, 537.83, 562.02, 562.03, 562.12, 562.13, 568.81, 569.3, 569.85, 578.x
  Procedure code: 44.43                                                                                              
  Major Intracranial Hemorrhage                                                                                      430, 431, 432.0, 432.1, 432.9, 852.0x, 852.2x, 852.4x, 853.0x,
  Major Other Hemorrhage                                                                                             285.1, 360.43, 362.43, 362.81, 363.61, 363.62, 363.72, 364.41, 372.72, 374.81, 376.32, 377.42, 379.23, 423.0x, 596.7x, 599.7x, 602.1x, 620.1, 621.4, 626.2, 626.5, 626.7, 626.8, 626.9, 719.1x, 782.7, 784.7, 784.8, 786.3x, 958.2, 997.02, 998.11
  Procedure code: 99.04                                                                                              

AF: atrial fibrillation; BMI: body mass index; HCPCS: Healthcare Common Procedural Coding System; ICD-9: International Classifications of Diseases, Ninth Edition; VTE: venous thromboembolism.

jcm-09-01633-t0A2_Table A2

###### 

Baseline characteristics of NVAF patients with obesity before PSM.

                                              Warfarin Cohort   Apixaban Cohort   Dabigatran Cohort   Rivaroxaban Cohort                            
  ------------------------------------------- ----------------- ----------------- ------------------- -------------------- ------- ------- -------- -------
  Sample Size                                 30,902                              21,242                                   7171            29,146   
  Age                                         72.8              8.8               71.5                9.9                  69.6    10.0    70.0     10.3
  18--54                                      1038              3.4%              1285                6.0%                 606     8.5%    2346     8.0%
  55--64                                      2895              9.4%              2793                13.1%                1112    15.5%   4636     15.9%
  65--74                                      14,044            45.4%             8977                42.3%                3215    44.8%   12,486   42.8%
  ≥75                                         12,925            41.8%             8187                38.5%                2238    31.2%   9678     33.2%
  Gender                                                                                                                                            
  Male                                        15,974            51.7%             11,027              51.9%                4033    56.2%   15,647   53.7%
  Female                                      14,928            48.3%             10,215              48.1%                3138    43.8%   13,499   46.3%
  U.S. Geographic Region                                                                                                                            
  Northeast                                   5330              17.2%             3405                16.0%                1367    19.1%   4944     17.0%
  Midwest                                     9934              32.1%             4980                23.4%                1701    23.7%   7372     25.3%
  South                                       10,693            34.6%             10,103              47.6%                3017    42.1%   12,705   43.6%
  West                                        4857              15.7%             2676                12.6%                1052    14.7%   3988     13.7%
  Other                                       88                0.3%              78                  0.4%                 34      0.5%    137      0.5%
  Race (only for Humana and Medicare)                                                                                                               
  White                                       21,856            88.2%             14,231              89.1%                4376    88.0%   18,059   88.5%
  Black                                       1917              7.7%              1031                6.5%                 328     6.6%    1277     6.3%
  Other                                       1004              4.1%              711                 4.5%                 270     5.4%    1075     5.3%
  Baseline Comorbidity                                                                                                                              
  Deyo--Charlson Comorbidity Index            4.5               3.1               3.7                 2.9                  3.3     2.8     3.4      2.8
  CHADS~2~ Score                              2.8               1.3               2.5                 1.3                  2.4     1.3     2.4      1.3
  0                                           567               1.8%              594                 2.8%                 262     3.7%    1031     3.5%
  1                                           3942              12.8%             4185                19.7%                1572    21.9%   6374     21.9%
  2                                           8708              28.2%             6475                30.5%                2354    32.8%   9320     32.0%
  3+                                          17,685            57.2%             9988                47.0%                2983    41.6%   12,421   42.6%
  CHA~2~DS~2~-VASc Score                      4.3               1.6               3.9                 1.7                  3.7     1.7     3.7      1.7
  0                                           254               0.8%              349                 1.6%                 169     2.4%    646      2.2%
  1                                           796               2.6%              1045                4.9%                 506     7.1%    1936     6.6%
  2                                           2669              8.6%              2842                13.4%                1112    15.5%   4466     15.3%
  3                                           5836              18.9%             4464                21.0%                1610    22.5%   6305     21.6%
  4+                                          21,347            69.1%             12,542              59.0%                3774    52.6%   15,793   54.2%
  HAS-BLED Score                              3.5               1.4               3.2                 1.4                  3.0     1.4     3.1      1.4
  0                                           246               0.8%              281                 1.3%                 133     1.9%    553      1.9%
  1                                           1501              4.9%              1728                8.1%                 787     11.0%   2993     10.3%
  2                                           5661              18.3%             4657                21.9%                1793    25.0%   6992     24.0%
  3+                                          23,494            76.0%             14,576              68.6%                4458    62.2%   18,608   63.8%
  Bleeding History                            8496              27.5%             4425                20.8%                1329    18.5%   5822     20.0%
  Congestive Heart Failure                    14,722            47.6%             8068                38.0%                2487    34.7%   10,246   35.2%
  Diabetes Mellitus                           18,984            61.4%             11,390              53.6%                3778    52.7%   15,164   52.0%
  Hypertension                                29,379            95.1%             20,022              94.3%                6670    93.0%   27,161   93.2%
  Renal Disease                               12,934            41.9%             6445                30.3%                1720    24.0%   7489     25.7%
  Liver Disease                               2382              7.7%              1471                6.9%                 472     6.6%    2051     7.0%
  Myocardial Infarction                       4905              15.9%             2528                11.9%                722     10.1%   3235     11.1%
  Dyspepsia or Stomach Discomfort             7974              25.8%             5014                23.6%                1555    21.7%   6711     23.0%
  Non-Stroke/SE Peripheral Vascular Disease   19,062            61.7%             11,847              55.8%                3745    52.2%   15,274   52.4%
  Stroke/SE                                   4669              15.1%             2307                10.9%                723     10.1%   2937     10.1%
  Transient Ischemic Attack                   2295              7.4%              1397                6.6%                 445     6.2%    1787     6.1%
  Anemia and Coagulation Defects              12,178            39.4%             6478                30.5%                1845    25.7%   7949     27.3%
  Alcoholism                                  788               2.5%              517                 2.4%                 203     2.8%    874      3.0%
  Peripheral Artery Disease                   8357              27.0%             4563                21.5%                1339    18.7%   6000     20.6%
  Coronary Artery Disease                     16,865            54.6%             10,616              50.0%                3315    46.2%   13,513   46.4%
  Dyslipidemia                                25,528            82.6%             17,510              82.4%                5775    80.5%   23,533   80.7%
  Morbid Obesity                              12,779            41.4%             7962                37.5%                2752    38.4%   11,447   39.3%
  Baseline Medication Use                                                                                                                           
  ACEi/ARB                                    21,240            68.7%             14,912              70.2%                4964    69.2%   20,093   68.9%
  Amiodarone                                  4143              13.4%             2839                13.4%                859     12.0%   3576     12.3%
  Beta Blockers                               19,252            62.3%             13,486              63.5%                4347    60.6%   18,192   62.4%
  H2-Receptor Antagonist                      2663              8.6%              1569                7.4%                 485     6.8%    2081     7.1%
  Proton Pump Inhibitor                       10,973            35.5%             7530                35.4%                2354    32.8%   9922     34.0%
  Statins                                     20,288            65.7%             13,579              63.9%                4324    60.3%   17,928   61.5%
  Anti-Platelets                              6869              22.2%             4597                21.6%                1244    17.3%   5488     18.8%
  NSAIDS                                      8019              25.9%             6379                30.0%                2194    30.6%   9165     31.4%
  Dose of the Index Prescription                                                                                                                    
  Standard Dose ^1^                                                               18,290              86.1%                6254    87.2%   22,908   78.6%
  Lower Dose ^2^                                                                  2952                13.9%                917     12.8%   6238     21.4%
  Follow-up Time (in Days)                    232.4             211.1             175.6               159.1                220.5   217.9   217.9    206.4
  Median                                      154                                 120                                      126             139      

ACEi/ARB: angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; CHA~2~DS~2~-VASc: congestive heart failure, hypertension, aged ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65--74 years, sex category; HAS-BLED: hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratios, elderly, drugs and alcohol; NSAIDs: non-steroidal anti-inflammatory drugs; NVAF: nonvalvular atrial fibrillation; PSM: propensity score matching; SD: standard deviation; SE: systemic embolism. **^1^** Standard dose: 5 mg apixaban, 150 mg dabigatran, 20 mg rivaroxaban. ^2^ Lower dose: 2.5 mg apixaban, 75 mg dabigatran, 10 or 15 mg rivaroxaban; 1311 patients were prescribed 10 mg of rivaroxaban in the rivaroxaban cohort.
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###### 

Outcomes characteristics of NVAF patients before PSM.

                                                         Warfarin Cohort   Apixaban Cohort   Dabigatran Cohort   Rivaroxaban Cohort                            
  ------------------------------------------------------ ----------------- ----------------- ------------------- -------------------- ------- ------- -------- -------
  Sample Size                                            30,902                              21,242                                   7171            29,146   
  Discontinuation                                        17,553            56.8%             8035                37.8%                4100    57.2%   14,575   50.0%
  Time-to-Discontinuation                                165.3             163.8             114.9               117.0                141.4   152.7   143.6    153.1
  Switch                                                                                     787                 3.7%                 748     10.4%   1972     6.8%
  Time-to-Switch                                                                             94.8                103.0                116.2   136.2   122.7    142.4
  Stroke/SE ^1^                                          406               1.3%              132                 0.6%                 67      0.9%    226      0.8%
  Hemorrhagic Stroke                                     115               0.4%              23                  0.1%                                 41       0.1%
  Ischemic Stroke                                        276               0.9%              107                 0.5%                 56      0.8%    170      0.6%
  Systemic Embolism                                      20                0.1%                                                                       17       0.1%
  Major Bleeding                                         1491              4.8%              399                 1.9%                 174     2.4%    1050     3.6%
  Gastrointestinal Bleeding                              721               2.3%              195                 0.9%                 110     1.5%    612      2.1%
  Intracranial Hemorrhage                                190               0.6%              38                  0.2%                 17      0.2%    67       0.2%
  Other Sites                                            676               2.2%              187                 0.9%                 55      0.8%    447      1.5%
  Stroke/SE Incidence Rate (per 100 person-years)        2.0                                 1.3                                      1.5             1.3      
  Major Bleeding Incidence Rate (per 100 person-years)   7.6                                 3.9                                      4.0             6.0      

NVAF: nonvalvular atrial fibrillation; PSM: propensity score matching; SD: standard deviation; SE: systemic embolism. ^1^ For some cohorts, the number of patients with a stroke event is \<11, which cannot be presented per the data use agreement.
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###### 

Baseline characteristics among NVAF patients with obesity after propensity score matching---NOACs vs. warfarin.

                                                  Warfarin Cohort   Apixaban Cohort   Warfarin Cohort   Dabigatran Cohort   Warfarin Cohort   Rivaroxaban Cohort                                                                    
  ----------------------------------------------- ----------------- ----------------- ----------------- ------------------- ----------------- -------------------- ------- ------- ------- ------ -------- ------- -------- ------- ------
  Sample Size                                     18,181                              18,181                                                  6646                         6646                   22,053           22,053           
  Age ^2^                                         72.7              8.8               72.8              9.0                 1.52              70.9                 9.3     70.7    9.1     1.51   72.3     8.9     72.3     8.8     0.21
  18--54                                          655               3.6%              659               3.6%                0.12              370                  5.6%    391     5.9%    1.36   865      3.9%    828      3.8%    0.87
  55--64                                          1746              9.6%              1709              9.4%                0.69              901                  13.6%   879     13.2%   0.97   2197     10.0%   2210     10.0%   0.20
  65--74                                          8192              45.1%             8184              45.0%               0.09              3120                 46.9%   3147    47.4%   0.81   10,347   46.9%   10,360   47.0%   0.12
  ≥75                                             7588              41.7%             7629              42.0%               0.46              2255                 33.9%   2229    33.5%   0.83   8644     39.2%   8655     39.2%   0.10
  Gender ^2^                                                                                                                                                                                                                        
  Male                                            9268              51.0%             9260              50.9%               0.09              3633                 54.7%   3632    54.6%   0.03   11,372   51.6%   11,313   51.3%   0.54
  Female                                          8913              49.0%             8921              49.1%               0.09              3013                 45.3%   3014    45.4%   0.03   10,681   48.4%   10,740   48.7%   0.54
  U.S. Geographic Region ^2^                                                                                                                                                                                                        
  Northeast                                       3132              17.2%             3137              17.3%               0.07              1264                 19.0%   1244    18.7%   0.77   3776     17.1%   3828     17.4%   0.62
  Midwest                                         4588              25.2%             4608              25.3%               0.25              1640                 24.7%   1624    24.4%   0.56   6275     28.5%   6174     28.0%   1.02
  South                                           7908              43.5%             7834              43.1%               0.82              2643                 39.8%   2724    41.0%   2.48   8560     38.8%   8624     39.1%   0.60
  West                                            2501              13.8%             2553              14.0%               0.83              1073                 16.1%   1024    15.4%   2.02   3377     15.3%   3365     15.3%   0.15
  Other                                           52                0.3%              49                0.3%                0.31              26                   0.4%    30      0.5%    0.93   65       0.3%    62       0.3%    0.25
  Race (Only for Humana and Medicare) ^2^                                                                                                                                                                                           
  White                                           13,165            89.0%             13,190            89.2%               0.54              4367                 88.8%   4338    88.2%   1.85   15,805   88.9%   15,796   88.9%   0.16
  Black                                           1010              6.8%              981               6.6%                0.78              298                  6.1%    324     6.6%    2.17   1158     6.5%    1178     6.6%    0.45
  Other                                           619               4.2%              623               4.2%                0.13              251                  5.1%    254     5.2%    0.28   812      4.6%    801      4.5%    0.30
  Baseline Comorbidity                                                                                                                                                                                                              
  Deyo--Charlson Comorbidity Index ^2^            4.0               2.9               3.9               2.9                 0.92              3.5                  2.9     3.5     2.8     3.05   3.9      2.9     3.9      2.9     0.27
  CHA~2~DS~2~-VASc Score                          4.2               1.6               4.1               1.6                 0.61              3.9                  1.6     3.8     1.7     1.99   4.1      1.6     4.1      1.6     0.12
  0                                               198               1.1%              165               0.9%                1.83              96                   1.4%    107     1.6%    1.35   229      1.0%    222      1.0%    0.32
  1                                               544               3.0%              565               3.1%                0.67              313                  4.7%    324     4.9%    0.77   731      3.3%    751      3.4%    0.50
  2                                               1848              10.2%             2029              11.2%               3.23              880                  13.2%   951     14.3%   3.10   2306     10.5%   2540     11.5%   3.39
  3                                               3729              20.5%             3718              20.4%               0.15              1559                 23.5%   1534    23.1%   0.89   4775     21.7%   4596     20.8%   1.98
  4+                                              11,862            65.2%             11,704            64.4%               1.82              3798                 57.1%   3730    56.1%   2.06   14,012   63.5%   13,944   63.2%   0.64
  HAS-BLED Score ^3^                              3.4               1.3               3.4               1.3                 0.54              3.1                  1.3     3.1     1.3     1.47   3.3      1.3     3.3      1.3     0.39
  0                                               184               1.0%              144               0.8%                2.33              96                   1.4%    93      1.4%    0.38   224      1.0%    198      0.9%    1.21
  1                                               991               5.5%              1063              5.8%                1.72              567                  8.5%    565     8.5%    0.11   1289     5.8%    1402     6.4%    2.14
  2                                               3799              20.9%             3696              20.3%               1.40              1585                 23.8%   1631    24.5%   1.62   4851     22.0%   4738     21.5%   1.24
  3+                                              13,207            72.6%             13,278            73.0%               0.88              4398                 66.2%   4357    65.6%   1.30   15,689   71.1%   15,715   71.3%   0.26
  Bleeding History ^2^                            4171              22.9%             4127              22.7%               0.58              1346                 20.3%   1294    19.5%   1.96   5015     22.7%   5046     22.9%   0.33
  Congestive Heart Failure ^2^                    7553              41.5%             7485              41.2%               0.76              2436                 36.7%   2424    36.5%   0.37   8926     40.5%   8877     40.3%   0.45
  Diabetes Mellitus ^2^                           10,265            56.5%             10,297            56.6%               0.36              3716                 55.9%   3611    54.3%   3.18   12,438   56.4%   12,435   56.4%   0.03
  Hypertension ^2^                                17,276            95.0%             17,273            95.0%               0.08              6235                 93.8%   6223    93.6%   0.74   20,842   94.5%   20,833   94.5%   0.18
  Renal Disease ^2^                               6173              34.0%             6166              33.9%               0.08              1758                 26.5%   1697    25.5%   2.09   6893     31.3%   6891     31.2%   0.02
  Liver Disease ^2^                               1280              7.0%              1271              7.0%                0.19              472                  7.1%    453     6.8%    1.12   1601     7.3%    1620     7.3%    0.33
  Myocardial Infarction ^2^                       2369              13.0%             2343              12.9%               0.43              700                  10.5%   711     10.7%   0.54   2771     12.6%   2794     12.7%   0.31
  Dyspepsia or Stomach Discomfort ^2^             4502              24.8%             4430              24.4%               0.92              1486                 22.4%   1488    22.4%   0.07   5375     24.4%   5390     24.4%   0.16
  Non-Stroke/SE Peripheral Vascular Disease ^2^   10,753            59.1%             10,676            58.7%               0.86              3639                 54.8%   3624    54.5%   0.45   12,750   57.8%   12,759   57.9%   0.08
  Stroke/SE ^2^                                   2273              12.5%             2183              12.0%               1.51              739                  11.1%   710     10.7%   1.40   2699     12.2%   2639     12.0%   0.83
  Transient Ischemic Attack ^2^                   1278              7.0%              1257              6.9%                0.45              456                  6.9%    432     6.5%    1.45   1511     6.9%    1510     6.8%    0.02
  Anemia and Coagulation Defects ^2^              6164              33.9%             6082              33.5%               0.95              1874                 28.2%   1814    27.3%   2.02   7167     32.5%   7105     32.2%   0.60
  Alcoholism ^2^                                  428               2.4%              429               2.4%                0.04              192                  2.9%    182     2.7%    0.91   621      2.8%    620      2.8%    0.03
  Peripheral Artery Disease                       4513              24.8%             4228              23.3%               3.67              1464                 22.0%   1319    19.8%   5.36   5287     24.0%   5282     24.0%   0.05
  Coronary Artery Disease                         9491              52.2%             9544              52.5%               0.58              3168                 47.7%   3197    48.1%   0.87   11,153   50.6%   11,261   51.1%   0.98
  Dyslipidemia ^2^                                15,199            83.6%             15,191            83.6%               0.12              5419                 81.5%   5402    81.3%   0.66   18,168   82.4%   18,237   82.7%   0.82
  Morbid Obesity                                  7207              39.6%             6777              37.3%               4.86              2619                 39.4%   2523    38.0%   2.97   8782     39.8%   8660     39.3%   1.13
  Baseline Medication Use ^2^                                                                                                                                                                                                       
  ACEi/ARB                                        12,771            70.2%             12,788            70.3%               0.20              4615                 69.4%   4651    70.0%   1.18   15,371   69.7%   15,345   69.6%   0.26
  Amiodarone                                      2429              13.4%             2446              13.5%               0.27              810                  12.2%   810     12.2%   0.00   2793     12.7%   2816     12.8%   0.31
  Beta Blockers                                   11,442            62.9%             11,562            63.6%               1.37              4051                 61.0%   4025    60.6%   0.80   13,732   62.3%   13,778   62.5%   0.43
  H2-Receptor Antagonist                          1438              7.9%              1419              7.8%                0.39              500                  7.5%    464     7.0%    2.09   1735     7.9%    1760     8.0%    0.42
  Proton Pump Inhibitor                           6477              35.6%             6510              35.8%               0.38              2259                 34.0%   2229    33.5%   0.95   7725     35.0%   7755     35.2%   0.29
  Statins                                         11,915            65.5%             11,913            65.5%               0.02              4213                 63.4%   4111    61.9%   3.17   14,141   64.1%   14,210   64.4%   0.65
  Anti-Platelets                                  4070              22.4%             4066              22.4%               0.05              1195                 18.0%   1215    18.3%   0.78   4606     20.9%   4585     20.8%   0.23
  NSAIDS                                          5211              28.7%             5255              28.9%               0.53              2025                 30.5%   2016    30.3%   0.29   6384     28.9%   6408     29.1%   0.24
  Dose of the Index Prescription                                                                                                                                                                                                    
  Standard Dose ^4^                                                                   15,410            84.8%                                                              5747    86.5%                           16,599   75.3%   
  Low Dose ^5^                                                                        2771              15.2%                                                              899     13.5%                           5454     24.7%   
  Follow-Up Time (in Days)                        236.3             213.8             176.2             160.2               31.85             236.8                211.3   222.5   219.7   6.60   237.7    213.5   221.0    208.6   7.92
  Median                                          157                                 120                                                     159                          128                    159              142              

ACEi/ARB: angiotensin converting enzyme inhibitors/angiotensin-receptor blockers; CHA~2~D~S2~-VASc: congestive heart failure, hypertension, aged ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65--74 years, sex category; HAS-BLED: hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratios, elderly, drugs and alcohol; NOACs: non-vitamin K oral anticoagulants; NSAIDs: non-steroidal anti-inflammatory drugs; NVAF: non-valvular atrial fibrillation; SD: standard deviation; SE: systemic embolism; STD: standardized difference. ^1^ Std difference = 100 ×\|actual std diff\|. Std difference greater than 10 is considered significant. ^2^ Variables used in propensity score matching. ^3^ As the INR value is not available in the databases, a modified HAS-BLED score was calculated with a range of 0 to 8. ^4^ Standard dose: 5 mg apixaban, 150 mg dabigatran, 20 mg rivaroxaban. ^5^ Lower dose: 2.5 mg apixaban, 75 mg dabigatran, 10 or 15 mg rivaroxaban; 1053 patients treated with rivaroxaban were prescribed 10 mg rivaroxaban.
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###### 

Baseline characteristics among NVAF patients with obesity after propensity score matching among NOACs vs. NOACs.

                                                  Apixaban Cohort   Dabigatran Cohort   Apixaban Cohort   Rivaroxaban Cohort   Dabigatran Cohort   Rivaroxaban Cohort                                                                    
  ----------------------------------------------- ----------------- ------------------- ----------------- -------------------- ------------------- -------------------- ------- -------- ------- ------- ------- ------- ------- ------- -------
  Sample Size                                     6884                                  6884                                                       20,431                       20,431                   7103            7103            
  Age ^2^                                         70.5              10.0                70.0              9.8                  4.23                71.5                 9.8     71.5     9.7     0.85    69.7    10.0    69.5    9.9     1.40
  18--54                                          510               7.4%                521               7.6%                 0.61                1200                 5.9%    1215     5.9%    0.31    590     8.3%    581     8.2%    0.46
  55--64                                          980               14.2%               988               14.4%                0.33                2586                 12.7%   2599     12.7%   0.19    1102    15.5%   1102    15.5%   0.00
  65--74                                          3069              44.6%               3159              45.9%                2.63                8828                 43.2%   8689     42.5%   1.37    3193    45.0%   3366    47.4%   4.89
  ≥75                                             2325              33.8%               2216              32.2%                3.37                7817                 38.3%   7928     38.8%   1.12    2218    31.2%   2054    28.9%   5.04
  Gender ^2^                                                                                                                                                                                                                             
  Male                                            3776              54.9%               3810              55.3%                0.99                10,596               51.9%   10,614   52.0%   0.18    3982    56.1%   4171    58.7%   5.38
  Female                                          3108              45.1%               3074              44.7%                0.99                9835                 48.1%   9817     48.0%   0.18    3121    43.9%   2932    41.3%   5.38
  U.S. Geographic Region ^2^                                                                                                                                                                                                             
  Northeast                                       1256              18.2%               1255              18.2%                0.04                3339                 16.3%   3356     16.4%   0.22    1345    18.9%   1445    20.3%   3.54
  Midwest                                         1624              23.6%               1640              23.8%                0.55                4850                 23.7%   4861     23.8%   0.13    1688    23.8%   1613    22.7%   2.50
  South                                           2966              43.1%               2962              43.0%                0.12                9563                 46.8%   9580     46.9%   0.17    2999    42.2%   2920    41.1%   2.26
  West                                            1008              14.6%               1000              14.5%                0.33                2606                 12.8%   2561     12.5%   0.66    1038    14.6%   1098    15.5%   2.36
  Other                                           30                0.4%                27                0.4%                 0.68                73                   0.4%    73       0.4%    0.00    33      0.5%    27      0.4%    1.30
  Race (Only for Humana and Medicare) ^2^                                                                                                                                                                                                
  White                                           4361              88.2%               4358              88.1%                0.19                13,910               89.2%   13,926   89.3%   0.33    4368    88.1%   4374    88.2%   0.37
  Black                                           321               6.5%                322               6.5%                 0.08                994                  6.4%    1001     6.4%    0.18    325     6.6%    318     6.4%    0.57
  Other                                           265               5.4%                267               5.4%                 0.18                692                  4.4%    669      4.3%    0.72    266     5.4%    267     5.4%    0.09
  Baseline Comorbidity                                                                                                                                                                                                                   
  Deyo--Charlson Comorbidity Index ^2^            3.3               2.8                 3.4               2.8                  0.27                3.6                  2.9     3.6      2.9     0.15    3.3     2.8     3.2     2.7     2.72
  CHA~2~DS~2~-VASc Score                          3.7               1.7                 3.7               1.7                  0.57                3.9                  1.7     3.9      1.7     0.72    3.7     1.7     3.6     1.7     4.04
  0                                               132               1.9%                142               2.1%                 1.04                326                  1.6%    337      1.6%    0.43    165     2.3%    167     2.4%    0.19
  1                                               442               6.4%                438               6.4%                 0.24                988                  4.8%    1025     5.0%    0.84    498     7.0%    516     7.3%    0.98
  2                                               1073              15.6%               1032              15.0%                1.65                2722                 13.3%   2642     12.9%   1.16    1100    15.5%   1173    16.5%   2.80
  3                                               1531              22.2%               1547              22.5%                0.56                4326                 21.2%   4221     20.7%   1.26    1594    22.4%   1612    22.7%   0.61
  4+                                              3706              53.8%               3725              54.1%                0.55                12,069               59.1%   12,206   59.7%   1.37    3746    52.7%   3635    51.2%   3.13
  HAS-BLED Score ^3^                              3.1               1.4                 3.1               1.3                  2.06                3.2                  1.4     3.2      1.4     0.10    3.0     1.4     3.0     1.3     4.61
  0                                               96                1.4%                112               1.6%                 1.91                266                  1.3%    288      1.4%    0.93    130     1.8%    145     2.0%    1.53
  1                                               695               10.1%               680               9.9%                 0.73                1640                 8.0%    1662     8.1%    0.40    773     10.9%   821     11.6%   2.14
  2                                               1646              23.9%               1708              24.8%                2.10                4508                 22.1%   4555     22.3%   0.55    1771    24.9%   1807    25.4%   1.17
  3+                                              4447              64.6%               4384              63.7%                1.91                14,017               68.6%   13,926   68.2%   0.96    4429    62.4%   4330    61.0%   2.87
  Bleeding History ^2^                            1290              18.7%               1296              18.8%                0.22                4268                 20.9%   4265     20.9%   0.04    1317    18.5%   1235    17.4%   3.01
  Congestive Heart Failure ^2^                    2459              35.7%               2430              35.3%                0.88                7737                 37.9%   7779     38.1%   0.42    2471    34.8%   2451    34.5%   0.59
  Diabetes Mellitus ^2^                           3553              51.6%               3645              52.9%                2.68                10,967               53.7%   11,007   53.9%   0.39    3740    52.7%   3773    53.1%   0.93
  Hypertension ^2^                                6418              93.2%               6435              93.5%                0.99                19,262               94.3%   19,266   94.3%   0.08    6611    93.1%   6569    92.5%   2.28
  Renal Disease ^2^                               1728              25.1%               1690              24.5%                1.28                6072                 29.7%   6109     29.9%   0.40    1708    24.0%   1580    22.2%   4.27
  Liver Disease ^2^                               448               6.5%                466               6.8%                 1.05                1423                 7.0%    1379     6.7%    0.85    471     6.6%    474     6.7%    0.17
  Myocardial Infarction ^2^                       711               10.3%               706               10.3%                0.24                2400                 11.7%   2426     11.9%   0.39    716     10.1%   692     9.7%    1.13
  Dyspepsia or Stomach Discomfort ^2^             1514              22.0%               1505              21.9%                0.32                4826                 23.6%   4768     23.3%   0.67    1544    21.7%   1478    20.8%   2.27
  Non-Stroke/SE Peripheral Vascular Disease ^2^   3676              53.4%               3648              53.0%                0.82                11,365               55.6%   11,484   56.2%   1.17    3712    52.3%   3710    52.2%   0.06
  Stroke/SE ^2^                                   720               10.5%               704               10.2%                0.76                2194                 10.7%   2192     10.7%   0.03    711     10.0%   733     10.3%   1.02
  Transient Ischemic Attack ^2^                   414               6.0%                427               6.2%                 0.79                1316                 6.4%    1339     6.6%    0.46    442     6.2%    444     6.3%    0.12
  Anemia and Coagulation Defects ^2^              1873              27.2%               1815              26.4%                1.90                6197                 30.3%   6242     30.6%   0.48    1838    25.9%   1709    24.1%   4.20
  Alcoholism ^2^                                  186               2.7%                195               2.8%                 0.80                483                  2.4%    471      2.3%    0.39    203     2.9%    221     3.1%    1.49
  Peripheral Artery Disease                       1350              19.6%               1311              19.0%                1.43                4364                 21.4%   4677     22.9%   3.69    1327    18.7%   1463    20.6%   4.82
  Coronary Artery Disease                         3281              47.7%               3230              46.9%                1.48                10,183               49.8%   10,138   49.6%   0.44    3285    46.2%   3222    45.4%   1.78
  Dyslipidemia ^2^                                5560              80.8%               5568              80.9%                0.30                16,857               82.5%   16,842   82.4%   0.19    5716    80.5%   5688    80.1%   0.99
  Morbid Obesity                                  2601              37.8%               2658              38.6%                1.70                7660                 37.5%   7896     38.6%   2.38    2726    38.4%   2735    38.5%   0.26
  Baseline Medication Use ^2^                                                                                                                                                                                                            
  ACEi/ARB                                        4805              69.8%               4799              69.7%                0.19                14,341               70.2%   14,312   70.1%   0.31    4922    69.3%   4929    69.4%   0.21
  Amiodarone                                      827               12.0%               836               12.1%                0.40                2671                 13.1%   2658     13.0%   0.19    849     12.0%   874     12.3%   1.08
  Beta Blockers                                   4287              62.3%               4198              61.0%                2.66                12,981               63.5%   12,917   63.2%   0.65    4311    60.7%   4260    60.0%   1.47
  H2-Receptor Antagonist                          493               7.2%                477               6.9%                 0.91                1496                 7.3%    1473     7.2%    0.43    482     6.8%    460     6.5%    1.24
  Proton Pump Inhibitor                           2301              33.4%               2275              33.0%                0.80                7222                 35.3%   7151     35.0%   0.73    2342    33.0%   2259    31.8%   2.50
  Statins                                         4212              61.2%               4193              60.9%                0.57                13,057               63.9%   13,149   64.4%   0.94    4285    60.3%   4189    59.0%   2.75
  Anti-Platelets                                  1312              19.1%               1221              17.7%                3.41                4328                 21.2%   4392     21.5%   0.76    1235    17.4%   1150    16.2%   3.20
  NSAIDS                                          2119              30.8%               2122              30.8%                0.09                6191                 30.3%   6230     30.5%   0.41    2183    30.7%   2104    29.6%   2.42
  Dose of the Index Prescription                                                                                                                                                                                                         
  Standard Dose ^4^                               6045              87.8%               5979              86.9%                2.88                17,634               86.3%   15,514   75.9%   26.75   6194    87.2%   5698    80.2%   18.99
  Low Dose ^5^                                    839               12.2%               905               13.1%                2.88                2797                 13.7%   4917     24.1%   15.45   909     12.8%   1405    19.8%   7.53
  Follow-Up Time (in Days)                        176.2             158.3               221.5             218.3                23.72               176.1                159.6   220.4    208.6   23.89   220.7   218.1   217.4   206.4   1.54
  Median                                          120                                   127                                                        120                          141                      127             140             

ACEi/ARB: angiotensin converting enzyme inhibitors/angiotensin-receptor blockers; CHA~2~DS~2~-VASc: congestive heart failure, hypertension, aged ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65--74 years, sex category; HAS-BLED: hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratios, elderly, drugs and alcohol; NOACs: non-vitamin K oral anticoagulants; NSAIDs: non-steroidal anti-inflammatory drugs; NVAF: non-valvular atrial fibrillation; PSM: propensity score matching; SD: standard deviation; SE: systemic embolism; STD: standardized difference. ^1^ Std difference = 100 ×\|actual std diff\|. Std difference greater than 10 is considered significant. ^2^ Variables used in propensity score matching. ^3^ As the INR value is not available in the databases, a modified HAS-BLED score was calculated with a range of 0 to 8. ^4^ Standard dose: 5 mg apixaban, 150 mg dabigatran, 20 mg rivaroxaban. ^5^ Lower dose: 2.5 mg apixaban, 75 mg dabigatran, 10 or 15 mg rivaroxaban; 950 and 310 patients were prescribed 10 mg of rivaroxaban in the apixaban-rivaroxaban and dabigatran-rivaroxaban cohorts, respectively.

###### 

Cumulative incidence of major bleeding and stroke/systemic embolism. (**A**) Major bleeding for apixaban vs. warfarin; (**B**) Stroke/systemic embolism for apixaban vs. warfarin; (**C**) Major bleeding for dabigatran vs. warfarin; (**D**) Stroke/systemic embolism for dabigatran vs. warfarin; (**E**) Major bleeding for rivaroxaban vs. warfarin; (**F**) Stroke/systemic embolism for rivaroxaban vs. warfarin; (**G**) Major bleeding for apixaban vs. dabigatran; (**H**) Stroke/systemic embolism for apixaban vs. dabigatran; (**I**) Major bleeding for apixaban vs. rivaroxaban; (**J**) Stroke/systemic embolism for apixaban vs. rivaroxaban; (**K**) Major bleeding for dabigatran vs. rivaroxaban; (**L**) Stroke/systemic embolism for dabigatran vs. rivaroxaban.
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![Patient selection figure. AF: atrial fibrillation; OAC: oral anticoagulant; VTE: venous thromboembolism. Edoxaban was excluded from the final population due to a small sample size.](jcm-09-01633-g001){#jcm-09-01633-f001}

###### 

Incidence rates and hazard ratios for stroke/SE and major bleeding among NOACs vs. warfarin and NOACs vs. NOACs. (**A**) NOACs vs. warfarin. (**B**) NOACs vs. NOACs. CI: confidence interval; GI: gastrointestinal; ICH: intracranial hemorrhage; NOACs: non-vitamin K oral anticoagulants; ref: reference; SE: systemic embolism.
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###### 

Baseline characteristics among NVAF patients with obesity after propensity score matching.

  -------------------------------------------------------------------------------------------------------------------------- --------------------- ----------------------- ----------------------- ------------------------ ------------------------ ------------------------ ---------- -------------- ---------- -------------- ---------- -------
  (**A**) Baseline Characteristics among NVAF Patients with Obesity after Propensity Score Matching---NOACs vs. Warfarin.                                                                                                                                                                                                                    
                                                                                                                             **Apixaban Cohort**   **Warfarin Cohort**     **Dabigatran Cohort**   **Warfarin Cohort**      **Rivaroxaban Cohort**   **Warfarin Cohort**                                                                     
  ***n*/Mean**                                                                                                               **%/SD**              ***n*/Mean**            **%/SD**                ***n*/Mean**             **%/SD**                 ***n*/Mean**             **%/SD**   ***n*/Mean**   **%/SD**   ***n*/Mean**   **%/SD**   
  Sample Size                                                                                                                18,181                                        18,181                                           6646                                              6646                      22,053                    22,053     
  Age                                                                                                                        72.8                  9.0                     72.7                    8.8                      70.7                     9.1                      70.9       9.3            72.3       8.8            72.3       8.9
  Gender                                                                                                                                                                                                                                                                                                                                     
  Male                                                                                                                       9260                  50.9%                   9268                    51.0%                    3632                     54.6%                    3633       54.7%          11,313     51.3%          11,372     51.6%
  Female                                                                                                                     8921                  49.1%                   8913                    49.0%                    3014                     45.4%                    3013       45.3%          10,740     48.7%          10,681     48.4%
  Baseline Comorbidity                                                                                                                                                                                                                                                                                                                       
  Deyo--Charlson Comorbidity Index                                                                                           3.9                   2.9                     4.0                     2.9                      3.5                      2.8                      3.5        2.9            3.9        2.9            3.9        2.9
  CHA~2~DS~2~-VASc Score                                                                                                     4.1                   1.6                     4.2                     1.6                      3.8                      1.7                      3.9        1.6            4.1        1.6            4.1        1.6
  HAS-BLED Score ^1^                                                                                                         3.4                   1.3                     3.4                     1.3                      3.1                      1.3                      3.1        1.3            3.3        1.3            3.3        1.3
  Dose of the Index Prescription                                                                                                                                                                                                                                                                                                             
  Standard Dose ^2^                                                                                                          15,410                84.8%                                                                    5747                     86.5%                                              16,599     75.3%                     
  Low Dose ^3^                                                                                                               2771                  15.2%                                                                    899                      13.5%                                              5454       24.7%                     
  Follow-Up Time (in Days)                                                                                                   176.2                 160.2                   236.3                   213.8                    222.5                    219.7                    236.8      211.3          221.0      208.6          237.7      213.5
  Median                                                                                                                     120                                           157                                              128                                               159                       142                       159        
  (**B**) Baseline Characteristics among NVAF Patients with Obesity after Propensity Score Matching among NOACs vs. NOACs.                                                                                                                                                                                                                   
                                                                                                                             **Apixaban Cohort**   **Dabigatran Cohort**   **Apixaban Cohort**     **Rivaroxaban Cohort**   **Dabigatran Cohort**    **Rivaroxaban Cohort**                                                                  
  ***n*/Mean**                                                                                                               **%/SD**              ***n*/Mean**            **%/SD**                ***n*/Mean**             **%/SD**                 ***n*/Mean**             **%/SD**   ***n*/Mean**   **%/SD**   ***n*/Mean**   **%/SD**   
  Sample Size                                                                                                                6884                                          6884                                             20,431                                            20,431                    7103                      7103       
  Age                                                                                                                        70.5                  10.0                    70.0                    9.8                      71.5                     9.8                      71.5       9.7            69.7       10.0           69.5       9.9
  Gender                                                                                                                                                                                                                                                                                                                                     
  Male                                                                                                                       3776                  54.9%                   3810                    55.3%                    10,596                   51.9%                    10,614     52.0%          3982       56.1%          4171       58.7%
  Female                                                                                                                     3108                  45.1%                   3074                    44.7%                    9835                     48.1%                    9817       48.0%          3121       43.9%          2932       41.3%
  Baseline Comorbidity                                                                                                                                                                                                                                                                                                                       
  Deyo--Charlson Comorbidity Index                                                                                           3.3                   2.8                     3.4                     2.8                      3.6                      2.9                      3.6        2.9            3.3        2.8            3.2        2.7
  CHA~2~DS~2~-VASc Score                                                                                                     3.7                   1.7                     3.7                     1.7                      3.9                      1.7                      3.9        1.7            3.7        1.7            3.6        1.7
  HAS-BLED Score ^1^                                                                                                         3.1                   1.4                     3.1                     1.3                      3.2                      1.4                      3.2        1.4            3.0        1.4            3.0        1.3
  Dose of the Index Prescription                                                                                                                                                                                                                                                                                                             
  Standard Dose ^2^                                                                                                          6045                  87.8%                   5979                    86.9%                    17,634                   86.3%                    15,514     75.9%          6194       87.2%          5698       80.2%
  Low Dose ^3^                                                                                                               839                   12.2%                   905                     13.1%                    2797                     13.7%                    4917       24.1%          909        12.8%          1405       19.8%
  Follow-Up Time (in Days)                                                                                                   176.2                 158.3                   221.5                   218.3                    176.1                    159.6                    220.4      208.6          220.7      218.1          217.4      206.4
  Median                                                                                                                     120                                           127                                              120                                               141                       127                       140        
  -------------------------------------------------------------------------------------------------------------------------- --------------------- ----------------------- ----------------------- ------------------------ ------------------------ ------------------------ ---------- -------------- ---------- -------------- ---------- -------

CHA~2~DS~2~-VASc: congestive heart failure, hypertension, aged ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65--74 years, sex category; HAS-BLED: hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratios, elderly, drugs and alcohol; NOACs: non-vitamin K oral anticoagulants; NVAF: non-valvular atrial fibrillation; SD: standard deviation. ^1^ As the INR value is not available in the databases, a modified HAS-BLED score was calculated with a range of 0 to 8. ^2^ Standard dose: 5 mg apixaban, 150 mg dabigatran, 20 mg rivaroxaban. ^3^ Lower dose: 2.5 mg apixaban, 75 mg dabigatran, 10 or 15 mg rivaroxaban; (**A**) 1053 patients treated with rivaroxaban were prescribed 10 mg rivaroxaban. (**B**) 950 and 310 patients were prescribed 10 mg of rivaroxaban in the apixaban-rivaroxaban and dabigatran-rivaroxaban cohorts, respectively.
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###### 

Incidence and hazard ratios of outcomes for standard-dosed NOACs vs. warfarin and NOACs vs. NOACs.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NOACs vs. Warfarin   NOACs vs. NOACs                                                                                                                                           
  -------------------- -------------------------------- -------------- -------------- --------- -------------------------------- -------------------- ----------- -------------- ---------
                       Incidence per 100 person-years   Hazard Ratio   *p*-value                Incidence per 100 person-years   Hazard Ratio         *p*-value                  

  (95% CI)             (95% CI)                                                                                                                                                  

                       5 mg Apixaban\                   Warfarin\                               5 mg Apixaban\                   150 mg Dabigatran\                              
                       *n* = 15,364                     *n* = 15,364                            *n* = 5904                       *n* = 5904                                      

  Stroke/SE            1.2                              1.9            0.61\          0.001     Stroke/SE                        1.3                  1.3         0.92\          0.733
                                                                       (0.46--0.81)                                                                               (0.55--1.52)   

  MB                   4.0                              6.3            0.57\          \<0.001   MB                               3.0                  3.7         0.77\          0.052
                                                                       (0.51--0.64)                                                                               (0.59--1.00)   

                       150 mg Dabigatran\               Warfarin\                               5 mg Apixaban\                   20 mg Rivaroxaban\                              
                       *n* = 5756                       *n* = 5756                              *n* = 16,553                     *n* = 16,553                                    

  Stroke/SE            1.3                              1.2            1.04\          0.843     Stroke/SE                        1.2                  1.2         0.93\          0.524
                                                                       (0.70--1.56)                                                                               (0.74--1.17)   

  MB                   3.8                              5.0            0.73\          0.024     MB                               3.3                  5.7         0.53\          \<0.001
                                                                       (0.56--0.96)                                                                               (0.47--0.60)   

                       20 mg Rivaroxaban\               Warfarin\                               150 mg Dabigatran\               20 mg Rivaroxaban\                              
                       *n* = 17,123                     *n* = 17,123                            *n* = 6169                       *n* = 6169                                      

  Stroke/SE            1.2                              1.6            0.75\          0.002     Stroke/SE                        1.3                  1.1         1.18\          0.322
                                                                       (0.62--0.90)                                                                               (0.85--1.65)   

  MB                   5.8                              5.5            1.04\          0.550     MB                               3.6                  4.9         0.74\          0.002
                                                                       (0.92--1.17)                                                                               (0.61--0.89)   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; MB: major bleeding; NOAC: non-vitamin K oral anticoagulants; SE: systemic embolism.
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###### 

Incidence rates and hazard ratios of NOACs vs. warfarin and NOACs vs. NOACs among patients with morbid obesity.

  NOACs vs. Warfarin   NOACs vs. NOACs                                                                                                                           
  -------------------- -------------------------------- -------------- ------------ --------- -------------------------------- -------------- ----------- ------ ---------
                       Incidence per 100 person-years   Hazard Ratio   *p*-value              Incidence per 100 person-years   Hazard Ratio   *p*-value          
  (95% CI)             (95% CI)                                                                                                                                  
                       Apixaban                         Warfarin                              Apixaban                         Dabigatran                        
  *n* = 6310           *n* = 6310                       *n* = 2373     *n* = 2373                                                                                
  Stroke/SE            1.3                              1.6            0.72         0.113     Stroke/SE                        0.7            1.3         0.51   0.175
  (0.48--1.08)         (0.19--1.35)                                                                                                                              
  MB                   4.6                              7.8            0.53         \<0.001   MB                               3.9            5.6         0.63   0.011
  (0.44--0.64)         (0.44--0.90)                                                                                                                              
                       Dabigatran                       Warfarin                              Apixaban                         Rivaroxaban                       
  *n* = 2342           *n* = 2342                       *n* = 7180     *n* = 7180                                                                                
  Stroke/SE            1.5                              1.9            0.77         0.304     Stroke/SE                        1.3            1.3         0.93   0.618
  (0.47--1.27)         (0.68--1.26)                                                                                                                              
  MB                   5.7                              7.4            0.76         0.088     MB                               4.0            7.9         0.47   \<0.001
  (0.56--1.04)         (0.39--0.56)                                                                                                                              
                       Rivaroxaban                      Warfarin                              Dabigatran                       Rivaroxaban                       
  *n* = 8055           *n* = 8055                       *n* = 2617     *n* = 2617                                                                                
  Stroke/SE            1.3                              1.8            0.72         0.079     Stroke/SE                        1.4            1.3         1.13   0.629
  (0.50--1.04)         (0.68--1.89)                                                                                                                              
  MB                   8.3                              7.6            1.09         0.317     MB                               5.4            6.7         0.79   0.086
  (0.92--1.28)         (0.61--1.03)                                                                                                                              

CI: confidence interval; MB: major bleeding; NOAC: non-vitamin K oral anticoagulants; SE: systemic embolism.
